• 1
    Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004; 10: 7792-7798.
  • 2
    Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood. 2004; 103: 1485-1494.
  • 3
    Jhanwar YS, Divgi C. Current status of therapy of solid tumors. J Nucl Med. 2005; 46( suppl 1): 141S-150S.
  • 4
    Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001; 46: 149-168.
  • 5
    Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002; 43: 693-713.
  • 6
    Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007; 25: 1396-1402.
  • 7
    Paganelli G, Grana C, Chinol M, et al. Antibody-guided 3-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med. 1999; 26: 348-357.
  • 8
    Garkavij M, Tennvall J, Strand SE, et al. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody. J Nucl Med. 1997; 38: 895-901.
  • 9
    Wilbur DS, Chyan MK, Hamlin DK, et al. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies. Bioconjug Chem. 2002; 13: 1079-1092.
  • 10
    Linden O, Kurkus J, Garkavij M, et al. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma. Cancer Biother Radiopharm. 2005; 20: 457-466.
  • 11
    Martensson L, Nilsson R, Ohlsson T, Sjogren HO, Strand SE, Tennvall J. Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion. J Nucl Med. 2007; 48: 269-276.
  • 12
    Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res. 1990; 50: 2183-2190.
  • 13
    Martensson L, Wang Z, Nilsson R, et al. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy. Clin Cancer Res. 2005; 11( 19 pt 2): 7104s-7108s.
  • 14
    Wang Z, Martensson L, Nilsson R, et al. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid and biotin before radiolabeling. Clin Cancer Res. 2005; 11( 19 pt 2): 7171s-7177s.
  • 15
    Green NM. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem J. 1965; 94: 23C-24C.
  • 16
    Martensson L, Nilsson R, Sjogren HO, Strand SE, Tennvall J. A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats. Artif Organs. 2007; 31: 312-316.
  • 17
    Sjogren HO, Isaksson M, Willner D, Hellstrom I, Hellstrom KE, Trail PA. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res. 1997; 57: 4530-4536.
  • 18
    Vallabhajosula S, Goldsmith SJ, Hamacher KA, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005; 46: 850-858.
  • 19
    Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005; 11( 19 pt 2): 7195s-7200s.
  • 20
    Saha GB. Physics and Radiobiology of Nuclear Medicine. New York, NY: Springer-Verlag; 2003: 196.
  • 21
    Hendry JH, Roberts SA. Analysis of dose-incidence relationships for marrow failure in different species, in terms of radiosensitivity of tissue-rescuing units. Radiat Res. 1990; 122: 155-160.
  • 22
    van Bekkum DW. Radiation sensitivity of the hemopoietic stem cell. Radiat Res. 1991; 128( 1 suppl): S4-S8.
  • 23
    Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 2007; 15: 457-464.
  • 24
    Nemecek ER, Green DJ, Fisher DR, et al. Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies. Cancer Biother Radiopharm. 2008; 23: 181-191.
  • 25
    Nemecek ER, Hamlin DK, Fisher DR, et al. Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. Clin Cancer Res. 2005; 11( 2 pt 1): 787-794.
  • 26
    Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996; 14: 1974-1981.
  • 27
    Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007; 131( 18 pt 2): 5556s-5563s.